Ocular Therapeutix
在场
高管
查看带有其 16 名主要高管的组织结构图
Ocular Therapeutix 搜索最多的简介
- Pravin Dugel, Director, Executive Chairman, President and Chief Ex...
- Suh Hong, Director
- Charles Warden, Lead Independent Director
高管在Ocular Therapeutix变化
- Pravin Dugel 曾任 Executive Chairman of the Board, 现升职为 Director, Executive Chairman, President and Chief Executive Officer (新闻发布的2024四月16号).
- Pravin Dugel已作为Executive Chairman of the Board加入公司 (新闻发布的2024二月23号).
- Steve Meyers 曾任 Senior Vice President, Commercial, 现升职为 Chief Commercial Officer (新闻发布的2024二月16号).
创建提醒
跟踪 Ocular Therapeutix 的高管变动
生物技术
Ocular Therapeutix 拥有 2,292 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Lycia Therapeutics 刚刚宣布为 107 筹款数百万美元。 (公布2024五月15号).
- Attovia Therapeutics 刚刚宣布为 150 筹款数百万美元。 (公布2024五月14号).
- Bruker has announced the acquisition of NanoString Technologies (公布2024五月13号).
生物技术 行业的其他推荐联系人
消息
Ocular Therapeutix 的最新新闻稿
- Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ To Report Second Quarter 2023 Financial Results | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ Announces Appointment of New Board Member | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results | Ocular Therapeutix, Inc.
- Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases | Ocular Therapeutix, Inc.
- View more press releases Close
通过电子邮件
